Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cue Biopharma ( (CUE) ) has issued an announcement.
On February 9, 2026, Cue Biopharma’s board appointed Chief Business Officer Lucinda Warren as Chief Financial and Business Officer, consolidating oversight of the company’s finance and business functions under a single executive. Warren, who now serves as principal financial and accounting officer, brings more than 30 years of pharmaceutical and biotechnology experience, including a decade leading end-to-end business development at Johnson & Johnson, while her compensation and employment terms at Cue Biopharma remain unchanged and free of related-party arrangements.
The appointment reflects Cue Biopharma’s reliance on Warren’s deep transactional and global business background to guide its financial and strategic direction without altering existing governance or incentive structures. The absence of new compensation, special arrangements, or family relationships with directors underscores a straightforward governance move aimed at operational continuity and strategic alignment rather than a restructuring of executive pay or control.
The most recent analyst rating on (CUE) stock is a Hold with a $0.29 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
The score is primarily held down by weak financial performance (declining revenue and very large losses) and bearish technicals (below key moving averages with negative MACD). Corporate events modestly offset this by extending cash runway and adding partnership upside, while valuation remains unattractive/unclear due to negative earnings and no dividend.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company operating in the pharmaceutical and biotech sectors, focused on developing therapies that leverage immune system modulation. The company’s leadership team includes executives with extensive global experience in business development, licensing and strategic alliances across major healthcare markets.
Average Trading Volume: 1,259,967
Technical Sentiment Signal: Sell
Current Market Cap: $30.78M
See more insights into CUE stock on TipRanks’ Stock Analysis page.